Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. Fluidigm’s systems consist of instruments, software, integrated fluidic circuits (IFCs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. Fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. The Company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality.